Cholangiocarcinoma is the second most common primary liver cancer after hepatocellular carcinoma, accounting for approximately 15% of cases. It is a rare cancer with increasing incidence and poor prognosis. Currently, surgical resection offers the only potential cure but most patients are not candidates for surgery. Artificial intelligence shows promise for improving cholangiocarcinoma management through early detection, identifying disease subtypes, and delivering targeted therapies to patients who could benefit.

1. ~15% of all primary liver cancers
2nd most common primary liver cancer
after hepatocellular carcinoma
Cholangiocarcinoma,
Cholangiocarcinoma,
a rare cancer …
a rare cancer …
Rare with only 0.3-6 new cases
per 100 000 people per year, but its
incidence is increasing

2. ... often
... often diagnosed too late
diagnosed too late ...
...
Asymptomatic during early stages
Histopathological or cytological analysis
necessary to confirm the diagnosis
Imaging patterns are not specific

3. ... highly
... highly heterogeneous
heterogeneous ...
...
Geographical variability
Anatomical variability
Genetic variability

4. ... with few
... with few therapeutic options
therapeutic options
and a
and a dismal prognosis
dismal prognosis.
.
Surgical resection is the only potentially
cure, but the majority of patients cannot
be operated
When the disease is unresectable,
only palliative treatment is possible
Low 5-year survival rate of 7-20%
7-20%

5. How can AI improve the
therapeutic management of
cholangiocarcinoma ?
?

6. Early
Early cholangiocarcinoma
cholangiocarcinoma
detection
detection
... and train an AI to recognize
cholangiocarcinoma in its early stages.
Build a large and diverse database ...
... ask top-level specialists to
analyze the medical images ...

7. Disease
Disease subtype discovery
subtype discovery
... and identify disease subtypes.
Aggregate multimodal data
(imaging, biological & clinical data) ...
... to better understand the
diversity of patients ...

8. Delivering next-generation
Delivering next-generation
therapies to
therapies to the
the right patients
right patients
... who could be efficiently identified
thanks to AI.
... but they will need to be delivered
to the right patients ...
Promising targeted and immuno-
therapies are being researched ...

9. Want to
Want to learn more
learn more?
?
Guerbet, winner of the
AIforHealth2020 challenge on the
radiological characterization of
cholangiocarcinomas
Our AI specialists have been developing an
AI algorithm able to automatically analyze
preoperative CT scans to predict patients recovery

10. Guerbet is engaging a research
partnership with AP-HP aimed at
developing artificial intelligence
methods to improve the
therapeutic management of
patients with cholangiocarcinoma.
What's
What's next
next?
?
Want to know more
about our AI project?
Ref : Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and
management. Nat. Rev. Gastroenterol. Hepatol. Nature Research; 2020. p. 557–588. doi: 10.1038/s41575-020-0310-z.